1.  Szigeti K, Lupski J. Charcot–Marie–Tooth disease. European Journal of Human Genetics. 2009; 17(6): 703-710. doi 10.1038/ejhg.2009.31
  2. ↑ Jump up to:2.0 2.1 2.2 Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot–Marie–Tooth disease. The Lancet Neurology. 2009; 8(7): 654-667. doi: 10.1016/s1474-4422(09)70110-3
  3. ↑ Jump up to:3.0 3.1 Krajewski K. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain. 2000;123(7):1516-1527. doi:10.1093/brain/123.7.1516
  4.  Vita G, La Foresta S, Russo M, Vita G, Messina S, Lunetta C et al. Sport activity in Charcot–Marie–Tooth disease: A case study of a Paralympic swimmer. Neuromuscular Disorders. 2016;26(9):614-618. doi: 10.1016/j.nmd.2016.06.002
  5.  Melzack R. The McGill pain questionnaire: from description to measurement. Anesthesiology, 2005; 103: 199-202. PMID:15983473
  6.  Shirley Ryan Abilitylab. Fatigue Severity Scale. Available from: (accessed 7/05/2019)
  7. ↑ Jump up to:7.0 7.1 7.2 McCorquodale D. Pucillo E. Johnson N. Management of Charcot-Marie-Tooth disease: improving long-term care with a multidisciplinary approach. Journal of Multidisciplinary Healthcare. 2016; 9: 7-19. DOI: 10.2147/JMDH.S69979
  8.  Graham R. Hughes R. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. Journal of Neurology, Neurosurgery & Psychiatry. 2006; 77: 973-976. DOI: 10.1136/jnnp.2005.081547
  9.  Shirley Ryan Abilitylab. Nine-hole peg test. Available from: (accessed 7/05/2019)
  10.  Shirley Ryan Abilitylab. Community Balance and Mobility Scale. Available from: (accessed 7/05/2019)
  11.  Shirley Ryan Abilitylab. 10 meter walk test. Available from: (accessed 7/05/2019)
  12. ↑ Jump up to:12.0 12.1 Abresch T, Carter G, Han J, McDonald C. Exercise in Neuromuscular Disease. Physical Medicine and Rehabilitation Clinics. 2012; 23: 653-673.
  13.  Pareyson D., Marchesi C. Diagnosis, natural history, and management of Charcot–Marie–Tooth disease. THE LANCET Neurology. 2009; 8: 654-667.
  14.  Shy M. Therapeutic Strategies for the Inherited Neuropathies. NeuroMolecular Medicine. 2006; 8: 271. doi:10.1385/NMM:8:1-2:255
  15. ↑ Jump up to:15.0 15.1 15.2 Skalsky AJ, McDonald CM. Prevention and management of limb contractures in neuromuscular diseases. Physical Medicine and Rehabilitation Clinics of North America. 2012; 23: 675-687. DOI: 10.1016/j.pmr.2012.06.009
  16. ↑ Jump up to:16.0 16.1 Menotti F, Laudani L, Damiani A, Mignogna T, Macaluso A. An anterior ankle-foot orthosis improves walking economy in charcot–marie–tooth type 1A patients. Prosthetics and Orthotics International. 2014; 38: 387-392.
  17. ↑ Jump up to:17.0 17.1 Phillips MF, Robertson Z, Killen B, White B. A pilot study of a crossover trial with randomized use of ankle-foot orthoses for people with charcot–marie–tooth disease. Clinical Rehabilitation. 2012; 26: 534-544. doi:10.1177/0269215511426802
  18. ↑ Jump up to:18.0 18.1 Ramdharry GM, Day BL, Reilly MM, Marsden JF. Foot drop splints improve proximal as well as distal leg control during gait in charcot‐marie‐tooth disease. Muscle & Nerve. 2012; 46: 512-519. doi: 10.1002/mus.23348
  19. ↑ Jump up to:19.0 19.1 Dufek JS, Neumann ES, Hawkins MC, O’Toole B. Functional and dynamic response characteristics of a custom composite ankle foot orthosis for charcot–marie–tooth patients. Gait & Posture. 2013;2014; 39: 308-313. doi: 10.1016/j.gaitpost.2013.07.121
  20.  Boentert M, Knop K, Schuhmacher C, Gess B, Okegwo A, Young P. Sleep disorders in charcot-marie-tooth disease type 1. Journal of Neurology, Neurosurgery, and Psychiatry. 2014; 85: 319-325. doi:10.1136/jnnp-2013-305296